Search research articles
Contact Us
Filters
Showing results (41-50 of 147) with videos related to
Page
of 15
Sort By:
AIDS (London, England)
|
May 11, 2002
Intracellular carbovir triphosphate levels in patients taking abacavir once a day
Marianne Harris, David Back, Sean Kewn, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 30, 2010
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
Laura Else, Victoria Watson, John Tjia, et al.
In Silico Pharmacology
|
December 16, 2014
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz
Marco Siccardi, Adeniyi Olagunju, Kay Seden, et al.
Pharmacogenetics and Genomics
|
June 21, 2014
CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults
Adeniyi Olagunju, Alessandro Schipani, Marco Siccardi, et al.
The Journal of Antimicrobial Chemotherapy
|
June 20, 2020
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
Felix Stader, Saye Khoo, Marcel Stoeckle, et al.
British Journal of Clinical Pharmacology
|
September 11, 2009
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC
Wai San Kwan, Omar Janneh, Ruben Hartkoorn, et al.
AIDS (London, England)
|
August 26, 2011
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients
Vincent Soriano, Kenneth E Sherman, Juergen Rockstroh, et al.
Antiviral Therapy
|
August 23, 2012
Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing
Mirjam de Roche, Marco Siccardi, Marcel Stoeckle, et al.
The Journal of Antimicrobial Chemotherapy
|
June 21, 2008
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
Jane E Mallewa, Edmund Wilkins, Javier Vilar, et al.
Journal of Hepatology
|
September 17, 2015
Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C"
Jean-Michel Pawlotsky, Alessio Aghemo, David Back, et al.
Page
of 15
Search research articles
Search
Showing results (41-50 of 147) with videos related to
Sort By:
Page
of 15
AIDS (London, England)
|
May 11, 2002
Intracellular carbovir triphosphate levels in patients taking abacavir once a day
Marianne Harris, David Back, Sean Kewn, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 30, 2010
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
Laura Else, Victoria Watson, John Tjia, et al.
In Silico Pharmacology
|
December 16, 2014
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz
Marco Siccardi, Adeniyi Olagunju, Kay Seden, et al.
Pharmacogenetics and Genomics
|
June 21, 2014
CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults
Adeniyi Olagunju, Alessandro Schipani, Marco Siccardi, et al.
The Journal of Antimicrobial Chemotherapy
|
June 20, 2020
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
Felix Stader, Saye Khoo, Marcel Stoeckle, et al.
British Journal of Clinical Pharmacology
|
September 11, 2009
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC
Wai San Kwan, Omar Janneh, Ruben Hartkoorn, et al.
AIDS (London, England)
|
August 26, 2011
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients
Vincent Soriano, Kenneth E Sherman, Juergen Rockstroh, et al.
Antiviral Therapy
|
August 23, 2012
Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing
Mirjam de Roche, Marco Siccardi, Marcel Stoeckle, et al.
The Journal of Antimicrobial Chemotherapy
|
June 21, 2008
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
Jane E Mallewa, Edmund Wilkins, Javier Vilar, et al.
Journal of Hepatology
|
September 17, 2015
Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C"
Jean-Michel Pawlotsky, Alessio Aghemo, David Back, et al.
Page
of 15